AMG 176 exhibits robust antitumor activity in combination with standard of care agents in models of acute myeloid leukemia

被引：0
|
作者：
Caenepeel, Sean [1 ]
Belmontes, Brian [1 ]
Osgood, Tao [1 ]
Cajulis, Elaina [1 ]
Coxon, Angela [1 ]
Canon, Jude [1 ]
Hughes, Paul E. [1 ]
机构：
[1] Amgen Inc, Thousand Oaks, CA USA
来源：
CANCER RESEARCH | 2019年 / 79卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2019-2180
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2180
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Identification of Genetic Pathways Controlling Resistance to Standard Combination Chemotherapy in Acute Myeloid Leukemia
    Ling, Victoria Y.
    Godfrey, William
    Jacquelin, Sebastien
    Straube, Jasmin
    Cooper, Leanne T.
    Bruedigam, Claudia
    Tey, Siok-Keen
    Bullinger, Lars
    Herold, Marco J.
    Bywater, Megan
    Lane, Steven W.
    BLOOD, 2018, 132
  • [22] Detection and management of acute myeloid leukemia measurable residual disease: is it standard of care?
    Paterno, Giovangiacinto
    Del Principe, Maria Ilaria
    Venditti, Adriano
    CURRENT OPINION IN HEMATOLOGY, 2020, 27 (02) : 81 - 87
  • [23] Addition of Cladribine: Improving Standard of Care in Newly Diagnosed Acute Myeloid Leukemia
    Mori, Shahram
    Rivera, Nahir
    Wazir, Mohammed
    Patel, Rushang D.
    Varela, Juan Carlos
    Zhu, Xiang
    Balls, Jason
    Smith, Tori
    Goldstein, Steven C.
    BLOOD, 2018, 132
  • [24] THE EFFECT OF STANDARD PATHWAY CARE FOR HEALTH PROMOTION IN PATIENTS WITH ACUTE MYELOID LEUKEMIA
    Huang, ZhiHong
    Wu, Juan
    Li, Ling
    Hu, Min
    Zhang, XueMei
    ACTA MEDICA MEDITERRANEA, 2022, 38 (02): : 1211 - 1215
  • [25] Cardiac Events in Patients with Acute Myeloid Leukemia Treated with Venetoclax in Combination with Hypomethylating Agents
    Johnson, Isla M.
    Bezerra, Evandro D.
    Farrukh, Faiqa
    McCullough, Kristen
    Al-Kali, Aref
    Alkhateeb, Hassan B.
    Begna, Kebede H.
    Litzow, Mark R.
    Hogan, William J.
    Shah, Mithun V.
    Patnaik, Mrinal M.
    Tefferi, Ayalew
    Gangat, Naseema
    BLOOD, 2021, 138
  • [26] Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes
    Daver, Naval
    Boddu, Prajwal
    Garcia-Manero, Guillermo
    Yadav, Shalini Singh
    Sharman, Padmanee
    Allison, James
    Kantarjian, Hagop
    LEUKEMIA, 2018, 32 (05) : 1094 - 1105
  • [27] Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes
    Naval Daver
    Prajwal Boddu
    Guillermo Garcia-Manero
    Shalini Singh Yadav
    Padmanee Sharma
    James Allison
    Hagop Kantarjian
    Leukemia, 2018, 32 : 1094 - 1105
  • [28] Palbociclib promotes the antitumor activity of Venetoclax plus Azacitidine against acute myeloid leukemia
    Wang, Anyou
    Fang, Mingmeng
    Jiang, Hui
    Wang, Dongyao
    Zhang, Xuhan
    Tang, Baolin
    Zhu, Xiaoyu
    Hu, Wanglai
    Liu, Xin
    BIOMEDICINE & PHARMACOTHERAPY, 2022, 153
  • [29] Antitumor activity of a potent MNK inhibitor NSP-1047 in acute myeloid leukemia
    Li, Bing
    Huang, Qionglin
    Zhang, Ke
    Zhang, Jianming
    CANCER RESEARCH, 2023, 83 (07)
  • [30] Alvocidib Potentiates the Activity of Venetoclax in Preclinical Models of Acute Myeloid Leukemia
    Whatcott, Clifford J.
    Bogenberger, James M.
    Kim, Wontak
    Haws, Hillary
    Hansen, Nanna
    Delman, Devora
    Sproat, Lisa
    Palmer, Jeanne
    Mesa, Ruben A.
    Peterson, Peter
    Siddiqui-Jain, Adam
    Weitman, Steven
    Bearss, David J.
    Warner, Steven L.
    Tibes, Raoul
    BLOOD, 2016, 128 (22)
12345